Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01429155 · ClinicalTrials.gov registry record
Outcomes in Hepatitis C After Living Donor Liver Transplantation in Association With Interleukin 28 B
A clinical trial, sponsored by Henry Ford Health System.
- Completed
- Registry status
- 36
- Enrollment target
NCT01429155: Completed study, sponsored by Henry Ford Health System.
NCT01429155 is a clinical trial that has completed, run by Henry Ford Health System. The registered enrollment target is 36 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01429155 has completed, sponsored by Henry Ford Health System.
- COMPLETED
- Registry status
- 36 participants
- Enrollment target
Study Summary
Hepatitis C is the leading cause of liver transplants in the USA. Given that there is a national organ shortage, living donor liver transplantation has became a viable option for patients with end stage liver disease who are not severely ill. Recently particular polymorphisms of IL-28B gene were reported to correlate with histological recurrence and antiviral treatment response after orthotopic liver transplantation for hepatitis C. Similar results have not been described yet in living donor liver transplant patients. There is data suggesting slightly inferior outcomes in living donor liver transplants when done for hepatitis C. The investigators postulate that such inferior outcomes may be related to IL28 polymorphism concordance (i.e., unfavorable recipient polymorphism patients receive similarly unfavorable polymorphism livers from their relatives).
Primary Outcome
Determine if sustained virological response is achieved after liver transplantation for hepatitis C with antiviral therapy (rivabirin and pegelated interferon) based on patient IL28B genotype
Interventions
- GENETIC Interleukin 28B genotype
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2011-08 |
| Est. Completion | 2013-03 |
What the finished NCT01429155 record still lists
NCT01429155 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 36 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Interleukin 28B genotype is the first listed.
NCT01429155 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01429155 about?
NCT01429155 is a clinical study titled "Outcomes in Hepatitis C After Living Donor Liver Transplantation in Association With Interleukin 28 B". Hepatitis C is the leading cause of liver transplants in the USA. Given that there is a national organ shortage, living donor liver transplantation has became a viable option for patients with end stage liver disease who are not severely ill. Recently particular polymorphisms of IL-28B gene were rep...
What is the current status of trial NCT01429155?
This trial is currently completed. The enrollment target is 36 participants. The study started on 2011-08. Estimated completion is 2013-03.
What interventions are being tested in trial NCT01429155?
The interventions under investigation include: Interleukin 28B genotype (GENETIC).
Who is sponsoring clinical trial NCT01429155?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia